Last Updated : December 13, 2023
Details
Generic Name:
pegcetacoplan
Project Status:
Pending
Therapeutic Area:
Geographic atrophy secondary to age-related macular degeneration
Manufacturer:
Apellis Canada, Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0810-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in adults.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Pegcetacoplan solution for injection is indicated in adults for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : December 13, 2023